Back to results
US 10,933,051 B2Granted
Carbapenem compounds and compositions for the treatment of bacterial infections
AssigneeFOB Synthesis, Inc.
InventorsWoo-Baeg Choi, Takashi Tomioka, Hyung-Yeul Joo, Phong Truong, Brian Min
Life of this patent
Estimating the term…
Abstract
The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
Claims17
A compound of Formula (I):
- or a pharmaceutically acceptable salt or prodrug thereof, wherein:
- R1 and R2 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- X is (1) an acylic or cyclic alkyl amino based linker, optionally substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, OR, CN, CONRR′, SR, or NRR′ or (2) a quaternary ammonium cation based linker, optionally substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, OR, CN, CONR2, SR, or NRR′;
- Y is a divalent —NR(C═O)—(CR2)n— or —(C═O)NR—(CR2)n— group, wherein n is 0, 1, or 2;
- R and R′ are each independently selected from H or alkyl;
- and
- Z is an aromatic or heteroaromatic ring, substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, OH, halogen, or hydroxyl protected by a hydroxyl protecting group.
5 more elements
A compound of Formula (IIa) or Formula (IIb):
- or a pharmaceutically acceptable salt or prodrug thereof, wherein:
- R1 and R2 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- Q1 and Q2 are each independently selected from a divalent —(CR2)p—W—(CR2)q—, optionally substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, OR, CN, CONRR′, SR, or NRR′;
- p and q are each independently 0, 1, or 2, and at least one of p or q is not 0;
- W is absent, —CONR—, or —NRCO—;
- Y1 and Y2 are each independently selected from a divalent —NR(C═O)—(CR2)n— or —(C═O)NR—(CR2)n— group, wherein n is 0, 1, or 2;
- Z1 and Z2 are each independently selected from an aromatic or heteroaromatic ring, substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- and
- R3 in Formula (IIb) is H or alkyl.
7 more elements
A compound of Formula (IIIa) or Formula (IIIb):
- or a pharmaceutically acceptable salt or prodrug thereof, wherein:
- R1, R2 and R3 are each independently selected from H or alkyl;
- P is H, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- V is a divalent —(CR2)n—(C═O)— or —(CR2)n— group, wherein n is 1, 2 or 3;
- Q1 and Q2 are each independently selected from a divalent —(CR2)p—W—(CR2)q—, optionally substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, OR, CN, CONRR′, SR, or NRR′;
- p and q are each independently 0, 1, or 2, and at least one of p or q is not 0;
- W is absent, —CONR—, or —NRCO—;
- Y1 and Y2 are each independently selected from a divalent —NR(C═O)—(CR2)n— or —(C═O)NR—(CR2)n— group, wherein n is 0, 1, or 2;
- Z1 and Z2 are each independently selected from an aromatic or heteroaromatic ring, substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, OH, halogen, or hydroxyl protected by a hydroxyl protecting group;
- and
- R5 in Formula (IIIb) is H or alkyl.
8 more elements
Dependencies are inferred from the claim text.